Verrica Pharmaceuticals Inc
VRCA
View Detailed Chart
4.390USD
+0.350+8.66%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
40.63MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+8.66%
5 Days
-7.58%
1 Month
-27.44%
6 Months
+607.49%
Year to Date
+527.14%
1 Year
+126.29%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
5
analysts
Buy
Current Rating
15.000
Target Price
+271.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.57M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 212.73.
Overvalued
The company’s latest PE is -0.57, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 8.91M shares, increasing 26.14% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 216.83K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.95.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Ticker SymbolVRCA
CompanyVerrica Pharmaceuticals Inc
CEODr. Jayson Rieger
Websitehttps://verrica.com/
Related Instruments
-1.43%
+1.17%
+0.22%
+0.52%
-1.03%
-0.73%
-0.02%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.27%
+1.19%
+0.92%
-0.87%
-0.23%
-0.83%
-1.12%
+0.31%
